Transcriptional regulatory protein NAC-1 and its downstream genes as therapeutic targets for the treatment of pancreatic cancer

• Project/Area Number: 25893136
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Digestive surgery
• Research Institution: Shimane University
• Principal Investigator: NAKAYAMA Naomi 島根大学, 医学部, 特別協力研究員 (60713188)
• Co-Investigator(Renkei-kenkyūsha): URANO Takeshi ; KATO Hiroaki
• Project Period (FY): 2013-08-30 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000); Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
• Keywords: がん関連転写制御因子 / 膵がん / NAC-1 / NAC1 / 膵癌 / 癌関連転写制御因子

Outline of Final Research Achievements

NAC1 is a BTB/POZ-domain transcription factor. It is overexpressed in ovarian serous carcinoma and NAC1 knock-down resulted in the apoptosis of ovarian cancer cell lines and rescued their sensitivity to chemotherapy, suggesting that NAC1 may be a potential therapeutic target. In this study, we elucidated that 1) NAC1 binds DNA through its BEN domain, 2) identification of the consensus DNA-binding sequence of NAC1, and 3) NAC1 forms a nuclear protein complex capable of modulating gene expression with an apparent molecular weight of 350-450 kDa.
To conquer pancreatic cancer, further analysis requires to find out true downstream genes of NAC1.

Research Products

• [Journal Article] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report. (2014)
  • Author(s): Ishikawa M, Nakayama K, Rahman MT, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Nakayama N and Miyazaki K.
  • Journal Title: Eur J Gynaecol Oncol Volume: 35 Pages: 443-448
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Microwave endometrial ablation at a frequency of 2.45 GHz for menorrhagia: analysis of treatment results at a single facility. (2014)
  • Author(s): Nakayama K, Ishibashi T, Ishikawa M, Katagiri A, Katagiri H, Iida K, Nakayama N, Miyazaki K.
  • Journal Title: J Obstet Gynaecol Res. Volume: 40 Issue: 1 Pages: 224-229
  • DOI: 10.1111/jog.12163
  • Peer Reviewed
• [Journal Article] KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas. (2013)
  • Author(s): Rahman MT, Nakayama K, Rahman M, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Sato E, Iida K, Nakayama N, Ishikawa N, Miyazaki K.
  • Journal Title: Int J Mol Sci. Volume: 14 Issue: 7 Pages: 13748-13762
  • DOI: 10.3390/ijms140713748
  • Peer Reviewed
• [Journal Article] ESR1 gene amplification in endometrial carcinomas: a clinicopathological analysis. (2013)
  • Author(s): Rahman MT, Nakayama K, Rahman M, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Sato E, Iida K, Ishikawa N, Nakayama N, Miyazaki K.
  • Journal Title: Anticancer Res. Volume: 33 Pages: 3775-3781
  • Peer Reviewed
• [Journal Article] Surgical treatment outcomes of serious chronic tubo-ovarian abscess: a single-center series of 20 cases. (2013)
  • Author(s): Nakayama K, Ishikawa M, Katagiri H, Katagiri A, Ishibashi T, Iida K, Nakayama N, Miyazaki K.
  • Journal Title: Clin Exp Obstet Gynecol. Volume: 40 Pages: 377-380
  • Peer Reviewed
• [Remarks] 島根大学 医学部 病態生化学講座 ホームページ
  • URL: http://www.med.shimane-u.ac.jp/biochem2/index.html
• [Remarks] 島根大学 医学部 病態生化学講座 ホームページ
  • URL: http://www.med.shimane-u.ac.jp/biochem2/index.html